(82) reported a 1.39-fold higher risk of irAEs (95% CI 1.21-1.59) in antibiotic-exposed NSCLC patients, particularly evident in those receiving anti-PD-1/PD-L1 therapies. This evidence concerns the gene CD274 and non-small cell lung carcinoma.